BioStock studio: Aptahem's CSO on the sepsis candidate Apta-1

08 April 2021 - 15:35

Luiza Jedlina, CSO and co-founder of Aptahem, visited the BioStock Studio at Medicon Village in Lund to talk about the company’s leading drug candidate Apta-1. Jedlina, who holds a PhD in molecular parasitology and immunology as well as a master’s degree in toxicology, has been instrumental in the establishment of Apta-1 as a potential treatment for “The Silent Killer”, sepsis.

Watch the interview with Aptahem's CSO Luiza Jedlina at

This is a press release from BioStock - Connecting Innovation & Capital

Provided by: Cision
Spotlight Stock Market (Sweden)
Aptahem AB
Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke and heart failure....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More